FRIDAY, Oct. 2, 2026 — More women are now being prescribed GLP-1 medications like Ozempic and Zepbound after giving birth.
A new study finds GLP-1 use among new mothers jumped from less than 0.1% in 2018 to nearly 2% in early 2025 — a...
Reference #18.b0f50f17.1791815218.b16247a7
https://errors.edgesuite.net/18.b0f50f17.1791815218.b16247a7
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Limiting Weight Regain After GLP-1s: Two Strategies Show Promise | 0 | 11.25 | 07-10-2026 |
| 2 | New Class Of Weight-Loss Drugs May Have Fewer Side Effects Than GLP-1s | 0 | 14.41 | 05-10-2026 |
| 3 | expert reaction to a systematic review and meta-analysis looking at preconception, pregnancy, and postnatal use of GLP-1 RAs in women with diabetes | 0 | 15.65 | 29-09-2026 |
| 4 | Препарат от ожирения оказался способен защитить мозг новорожденных | 0 | 7.54 | 29-09-2026 |
| 5 | Препарат от ожирения оказался способен защитить мозг новорожденных | 0 | 12.01 | 29-09-2026 |
| 6 | Daily oral GLP-1 medication linked to similar weight loss across three menopausal stages | 0 | 7.03 | 26-09-2026 |
| 7 | GLP-1-driven vitamin deficiency linked to rare brain disorder: Study | 0 | 10.4 | 12-09-2026 |
| 8 | The GLP-1 Debate Hits Pro Sports | 0 | 12.8 | 15-09-2026 |
| 9 | Ozempic and Wegovy may raise hair loss risk in some men | 0 | 9.41 | 13-09-2026 |